THE PATHOGENESIS OF MULTIPLE SCLEROSIS REVISITED

1 Noseworthy JH. Progress in determining the causes and treatment of multiple sclerosis. Nature 1999; 399:A40–7.

2 Steiner I Multiple Wirguin I. sclerosis – in need of a critical reappraisal. Med Hypotheses 2000; 54(1):99–106.

3 Bell JI Lathrop GM. Multiple loci for multiple sclerosis. Nat Genet 1996; 13:377–8.

4 Haines JL HA Terwedow Burgess K Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. Hum Mol Genet 1998; 7:1229–34.

5 Kalman B Lublin FD. The genetics of multiple sclerosis. A Review. Biomed Pharmacother 1999; 53(8):358–70.

6 von Deimling A W Krone Menon AG. Neurofibromatosis type 1: pathology, clinical features and molecular genetics. Brain Pathol 1995; 5:153–62.

7 Compston A Coles A. Multiple Sclerosis. Lancet 2002; 359:1221–31.

8 Johnson MR RE Ferner Bobrow M Detailed analysis of the oligodendrocyte myelin glycoprotein gene in four patients with neurofibromatosis 1 and primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2000; 68:643–6.

9Wrabetz, Feltri, Hanemann The molecular genetics of hereditary demyelinating neuropathies. In: Glial Cell Development – Basic Principles and Clinical Relevance. Eds. Jessen KR and Richardson WD. Oxford: Oxford University Press; 2001; 331–54.

10 Hohlfeld R Wiendl H. The ups and downs of multiple sclerosis therapeutics. Ann Neurol 2001; 49(3):281–4.

11 Rice GPA B Incorvaia Munari L Interferon in relapsingremitting multiple sclerosis (Cochrane Review). In: The Cochrane Library 1. Oxford: Update Software; 2002.

12 Stone LA JA Frank Albert PS The effect of interferonbeta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsingremitting multiple sclerosis. Ann Neurol 1995; 37:611–19.

13 Glanzmann E. Die Nervosen Komplicationen der Varizellen der Variola und Vakzine. Schweiz Med Wochenschr 1927; 57:145–54.

14 Remlinger P. Les paralysies du traitement antirabique. Ann Inst Pasteur 1928; 42(Suppl. 71).

15 Aujeszky A. Ueber Immunizierung gegen Wut mit normaler Nervensubstanz. Centralbl Bakt. Jena 1900; 27:5–10.

16 Bassoe P Grinker RR. Human rabies and rabies vaccine encephalomyelitis: A clinicopathological study. Arch Neurol Psychiat 1930; 23:1138–60.

17 Schwentker FF Rivers TM. The antibody response of rabbits to injections of emulsions and extracts of homologous brain. J Exp Med 1934; 60:559–74.

18 Rivers TM Schwentker FF. Encephalomyelitis accompanied by myelin destruction experimentally produced in monkeys. J Exp Med 1935; 61:689–702.

19 Kabat EA A Solf Bezer AE. Rapid production of acute disseminated encephalomyelitis in rhesus monkeys by injection of brain tissue with adjuvants. Science 1946; 104:362–3.

20 Freund J ER Stern Pisani TM. Isoallergic encephalomyelitis and radiculitis in guinea pigs after one injection of brain and mycobacteria in water-in-oil emulsion. J Immunol 1947; 57:179–94.

21 Adams RD. Chapter 5: A comparison of the morphology of the human demyelinating diseases and experimental ‘allergic encephalomyelitis’. In: ‘Allergic’ Encephalomyelitis. Eds. Kies MW, Alvord EC. Washington: Charles C Thomas;183–209.

22 Levine S. Relationship of experimental allergic encephalomyelitis to human disease. In: Immunological Disorders of the Nervous System. Ed. Rowland LP. Baltimore, Maryland:Williams &Wilkins. Res Publs Ass Nerv Ment Dist 1971; 49:33–49.

23 Raine CS. The Dale E McFarlin memorial lecture: the immunology of the multiple sclerosis lesion. Ann Neurol 1994; 36:S61–72.

24 Behan PO Currie S. Chapter 4: Acute disseminated encephalomyelitis. In: Clinical Neuroimmunology. London, Philadelphia and Toronto: Saunders Company; 1978; 49–61.

25 Graham DI PO Behan More IAR. Brain damage complicating septic shock. J Neurol Neurosurg Psychiat 1979; 42:19–28.

26 Russell DS. The neurological unity of acute haemorrhagic leukoencephalitis and acute disseminated encephalomyelitis. Brain 1955; 78:369–76.

27 Behan PO WMH Behan Feldman RG Cell-mediated hypersensitivity to neural antigens. Arch Neurol 1972; 27:145–52.

28 Behan PO MW Kies Lisak RP Immunologic mechanisms in experimental encephalomyelitis in nonhuman primates. Arch Neurol 1973; 29:4–9.

29McNair Scott TF. Post-infectious and vaccinial encephalitis. In: Medical Clinics of North America. Ed. Sweeney Jr, FJ. Philadelphia and London: W B Saunders; 1967; 701–17.

30 Behan PO N Geshwind Lamarche JB Delayed hypersensitivity to encephalitogenic protein in disseminated encephalitis. Lancet 1968; ii:1009–12.

31 Cohen JA Lisak RP. Acute disseminated encephalomyelitis. In: Eds. Aarli JA, Behan WMH, Behan PO. Clinical Neuroimmunology. Oxford: Blackwell Scientific Publications; 1987; 15, 192–213.

32 Lamarche JB PO Behan Segarra JM Recurrent acute necrotising haemorrhagic encephalopathy. Acta Neuropath 1972; 22:79–87.

33 Johnson DA DA Hafler Fallis RJ Cell-mediated immunity to myelin-associated glycoprotein, proteo-lipid protein, and myelin basic protein in multiple sclerosis. J Neuroimmunol 1986; 13:99–108.

34 Dawson J. The Histology of Disseminated Sclerosis. Trans R Soc Edinburgh 1916; 50:517–40.

35 Lumsden CE. Pathology of Multiple Sclerosis and Allied Demyelinating Diseases. In: Eds. McAlpine D, Compston ND, Lumsden CE. Multiple Sclerosis. Edinburgh: Livingstone; 1955; 208–93.

36 Adams CWM. Pathology of multiple sclerosis: progression of the lesion. Br Med Bull 1977; 3:15–20.

37 Popovich PG BT Stokes Whitacre CC. Concept of autoimmunity following spinal cord injury: possible roles for T lymphocytes in the traumatised central nervous system. J Neurosci Res1996; 45:349–63.

38 Paterson PY. Chapter 1: Neuroimmunology: an overview and personal perspective. In: Eds. Aarli JA, Behan WMH, Behan PO. Clinical Immunology. Oxford, London and Boston: Blackwell Scientific Publications; 1987; 3–25.

39 Aihara N H Tanno Hall JJ Immunocytochemical localisation of immunoglobulins in the rat brain: relationship to the blood-brain barrier. J Comp Neurol 1994; 342:481–96.

40 Noble LJ Distribution Wrathall JR. course time of protein extravasation in the rat spinal cord after contusive injury. Brain 1989; Res 482:57–66.

41 Fritz RB MJ Skeen Jen-Chou CH Major histocompatibility complex-linked control of the murine immune response to myelin basic protein. J Immunol 1985; 134:2328–32.

42 Baker D OA Rosenwasser O’Neil JK Genetic analysis of experimental allergic encephalomyelitis in mice. J Immunol 1995; 155:4046–51.

43 Zamvil SS Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol 1990; 8:579–621.

44 Martin R McFarland HF. Immunology of multiple sclerosis and experimental allergic encephalomyelitis. In: Eds. Raine CS, McFarland HF, Tourtellotte WW. Multiple Sclerosis. London: Chapman &Hall Medical; 1997; 221–39.

45 Lumsden C. The neuropathology of multiple sclerosis. In: Eds. Vinken PJ, Bruyn GW. Handbook of Clinical Neurology. Vol. 9. Multiple sclerosis and other demyelinating diseases. Amsterdam: Elsevier; 1970; 217–309.

46 Gulcher JR T Vartanian Stefansson K. Is multiple sclerosis an autoimmune disease? Clin Neurosci 1994; 2:246–52.

47 Oppenheimer DR. The cervical spine in multiple sclerosis. Neuropathol Appl Neuobiol 1978; 4:151–62.

48 Brain W Wilkinson M. The association of cervical spondylosis and disseminated sclerosis. Brain 1957; 80:456–78.

49 Burgerman R E Rigaminto Randle JM The association of cervical spondylosis and multiple sclerosis. Surg Neurol 1992; 38:265–70.

50 Chaudhuri A Behan PO. Acute cervical hyperextensionhyperflexion injury may precipitate and/or exacerbate symptomatic multiple sclerosis. Eur J Neurol 2001; 8:659–64.

51 Arstila AU PJ Riekkinen Rinne UK Studies of the pathogenesis of multiple sclerosis. Participation of lysosomes in demyelination in the CNS white matter. Europ Neurol 1973; 9:1–21.

52 Seitelberger F. Histochemistry of demyelinating diseases proper including allergic encephalomyelitis and Perlizaeus- Merzbacher’s disease. In: Ed. Cummings NJ. Modern Scientific Aspects of Neurology. London: Edward Arnold; 1960;146–87.

53 Guseo A Jellinger K. The significance of perivascular infiltrations in multiple sclerosis. J Neurol 1975; 211:51–60.

54 Prineas JW. The neuropathology of multiple sclerosis. In: Ed. Koetsier JC. Handbook of Clinical Neurology. Amsterdam: Elsevier Science Publishers B.V.; 1985; 3(47):213–57.

55 Sluga E. Beitrag zur Feinstruktur der Lasionen bei der multiplen Sklerose des Menschen. Wein Z Nervenheilkd Grenzgeb 1969; (Suppl. 2):59–69.

56 Prineas J. Pathology of the early lesion in multiple sclerosis. Hum Pathol 1975; 6:531–54.

57 Tanaka R Y Iwasaki Koprowski H. Ultrastructural studies of perivascular cuffing cells in multiple sclerosis brain. Am J Pathol 1975; 81(3):467–78.

58 Prineas JW EE Kwon Sternberger NH The distribution of myelin-associated glycoprotein and myelin basic protein in actively demyelinating multiple sclerosis lesions. J Neuroimmunol 1984; 6:251–64.

59 McGuinness MC Smith KD. Cerebral inflammation in Xlinked adrenoleukodystrophy (Review). Arch Immun Ther Exp (Warsz) 1999; 47(5):281–7.

60 Engelhardt JI J Tajti Appel SH. Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch Neurol 1993; 50:30–6.

61 Pezeshkpour GH Dalakas MC. Long-term changes in the spinal cords of patients with old poliomyelitis. Arch Neurol 1988; 45:505–08.

62 Adams CWM RN Poston Buk SJ Inflammatory vasculitis in multiple sclerosis. J Neurol Sci 1985; 69:269–83.

63 Lightman S WI McDonald Bird AC Retinal venous sheathing in optic neuritis. Its significance for the pathogenesis of multiple sclerosis. Brain 1987; 110:405–14.

64 Adams CWM. Histology and cellular features of multiple sclerosis. In: A Colour Atlas of Multiple Sclerosis and other myelin disorders. London: Wolfe Medical Pubs Ltd; 1989; 130–9.

65 Confavreux C S Vukusic Moreau T Relapses and progression of disability in multiple sclerosis. N Eng J Med 2000; 343:1430–8.

66 Revesz T D Kidd Thompson AJ Comparison of the pathology of primary and secondary progression of multiple sclerosis. Brain 1994; 117:759–65.

67 Ganter P C Prince Esiri MM. Spinal cord axonal loss in multiple sclerosis: a post-mortem study. Neuropathol Appl Neurobiol 1999; 25:459–67.

68 Isaac C DKB Li Genton M Multiple sclerosis: A serial study using MRI in relapsing patients. Neurology 1998; 38:1511–15.

69 Truyen L J Gheuens Parizel PM Long-term followup of multiple sclerosis by standardised, non-contrastenhanced magnetic resonance imaging. J Neurol Sci 1991; 106:35–40.

70 Brinkman CJJ WM Nillesen Hommes OR Cellmediated immunity in multiple sclerosis as determined by sensitivity of different lymphocyte populations to various brain tissue antigens. Ann Neurol 1982; 11:450–5.

71 Burns J A Rosenweig Zweiman B Isolation of myelin basic protein-reactive T-cell lines from normal human blood. Cell Immunol 1983; 81:435–40.

72 Hafler DA M Buchsbaum Johnson D Phenotypic and functional analysis of T-cells cloned directly from the blood and cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol 1985; 18:451–8.

73 Tournier-Lasserve E GA Hashim Bach MA. Human T-cell response to myelin basic protein in multiple sclerosis patients and healthy subjects. J Neurosci Res 1988; 19:149–56.

74 Richert JR DE McFarlin Rose JW Expansion of antigen-specific T-cells from cerebrospinal fluid of patients with multiple sclerosis. J Neuroimmunol 1983; 5:317–24.

75 Ben-Nun A RS Liblau Cohen L Restricted T-cell receptor gene usage by myelin basic protein-specific Tcell clones in multiple sclerosis. Predominant genes vary in individuals. Proc Natl Acad Sci USA 1991; 88:2466–70.

76 Martin R R Voskuhl Flerlage M Myelin basic proteinspecific T-Cell responses in identical twins discordant or concordant for multiple sclerosis. Ann Neurol 1993; 34:524–35.

77 Antel JP BGW Arnason Medof ME. Suppressor cell function in multiple sclerosis; correlation with clinical disease activity. Ann Neurol 1979; 5:338–49.

78 Quattrocchi KB EH Frank Miller CE Suppression of cellular immune activity following severe head injury. J Neurotrauma 1990; 7(2):77–87.

79 Thomas DGT CB Lannigan Behan PO. Impaired cellmediated immunity in human brain tumours. Lancet 1975; i:1389–90.

80 Antel JP MK Nicholas Bania MB Comparison of T8+ cell-mediated suppressor and cytotoxic functions in multiple sclerosis. J Neuroimmunol 1986; 12:215–24.

81 Rohowsky-Kochan C D Eiman Troiano R Decreased suppressor-inducer T lymphocytes in multiple sclerosis and other neurological diseases. J Neuroimmunol 1990; 28:161–6.

82 Freedman MS KL Muth Trotter JL Prospective serial analysis of interleukin-2 receptor in relapsing-remitting multiple sclerosis. Neurology 1992; 42:1596–601.

83 Quinn S. Human Trials. Scientists, Investors and Patients In the Quest for a Cure. Cambridge, MA:: Perseus Publishing; 2001.

84 Simpson JA. Myasthenia gravis. A new hypothesis. Scot Med J 1960; 5:419–36.

85 Behan PO Haniffah BAG. The genetics of myasthenia gravis. In: Ed. Lisak RP. Handbook of Myasthenia Gravis and Myasthenic Syndromes. New York: Marcel Dekker Inc (Pub); 1994; 165–91.

86 Shakir RA JM Hussien Trontelj JJ. Myasthenia gravis and neuromyelitis optica. J Neuroimmunol 1983; 4:161–5.

87 Aita FJ HD Snyder Reichl W. Myasthenia gravis and multiple sclerosis: an unusual combination of diseases. Neurology 1974; 24:72–5.

88 Warren SA Warren KG. Multiple sclerosis and diabetes mellitus: further evidence of a relationship. Can J Neurol Sci 1982; 9:415–19.

89 Alter M GT Sawyer Latham K. The frequency of diabetes mellitus in families of patients with multiple sclerosis. Neurology 1970; 20:619–21.

90 Broadley SA J Deans Sawcer SJ Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey. Brain 2000; 123:1102–11.

91 Heinzlef O S Alamowitch Sazdovitch S Autoimmune disease in families of French patients with multiple sclerosis. Acta Neurol Scand 1999; 100:1–5.

92 McDonald WI A Compston Edan G Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50:121–7.

93 Amato MP G Ponziani Bartolozzi ML A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials. J Neurol Sci 1999; 168:96–106.

94 O’Riordan JI AJ Thompson Kingsley DP The prognostic value of brain MRI in clinically isolated syndromes of the CNS: a 10-year follow-up. Brain 1998; 121:495–503.

95The Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomised, double-blinded, placebo-controlled clinical tria. Ann Neurol 1990; 27:591–605.

96 Likosky WH B Fireman Elmore R Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J Neurol Neurosurg Psychiat 1991; 54:1055–60.

97The Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991; 337:441–6.

98 Hauser SL DM Dawson Lehrich JR Intensive immunosuppression in progressive multiple sclerosis: a randomised, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Eng J Med 1993; 308:173–80.

99 Yudkin PL GW Ellison Ghezzi A Overview of azathioprine treatment in multiple sclerosis. Lancet 1991; 338:1051–5.

100 Compston A. Treatment and management of multiple sclerosis. In: McAlpine’s Multiple Sclerosis. 3rd edition. London: Churchill Livingston; 1998; 437–98.

101 Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 2002; 58(Suppl 4):S3–9.

102 Calabresi PA. Considerations in the treatment of relapsing-remitting multiple sclerosis. Neurology 2002; 58(Suppl 4):S10–22.

103 Beecher HK. The powerful placebo. JAMA 1955; 159:1602–6.

104 Behan PO ID Melville Durward WF Transfer-factor therapy in multiple sclerosis. Lancet 1976; i:988–90.

105 Behan PO. Dorsal column stimulation in multiple sclerosis. BMJ 1980; 2:1287–8.

106 Mayor S. Researchers claim clinical trials are reported with misleading statistics. BMJ 2002; 324:1353.

107 Clarke M P Alderson Chalmers I. Discussion sections in reports of controlled trials published in general medical journals. JAMA 2002; 287:2799–801.

108 Umehara F YF Qin Goto M Experimental autoimmune encephalomyelitis in the maturing central nervous system. Transfer of myelin basic protein-specific T line lymphocytes to neonatal Lewis rats. Lab Invest 1990; 62(2):147–55.

109 Oppenheimer DR. Acute encephalopathy in children. In: Eds. Whitty CWM, Hughes JT, MacCallum FO. Virus diseases and the Nervous System. Oxford and Edinburgh: Blackwell Scientific Publications; 1969.

110 Guilhoto LMRR CAM Osorio Machado LB. Paediatric multiple sclerosis report of 14 cases. Brain Devel 1995; 17:9–12.

111 Shaw CM Alvord EC. Multiple sclerosis beginning in infancy. J Child Neurol 1987; 2:252–6.

112 Brandt S C Gyldensted Offner H Multiple sclerosis with onset in a two-year-old boy. Neuropaediatrics 1981; 12(1):75–82.

113 Taylor D Cuendet F. Optic neuritis in childhood. In: Eds. Hess RF, Plant GT. Optic Neuritis Cambridge: Cambridge University Press; 73–85.

114 Berger JR WA Sheremata Resnick L Multiple sclerosis-like illness occurring with human immunodeficiency virus infection. Neurology 1989; 39:324–9.

115 Peterson K MK Rosenblum Powers JM Effect of brain irradiation on demyelinating lesions. Neurology 1993; 43:2105–12.

116 Oldendorf WH Cornford EM. A comparison of total body and local spinal cord irradiation in experimental allergic encephalomyelitis. J Neuropathol Exp Neurol 1997; 36:50–61.

117 Levine S Hoenig EM. Induced localisation of allergic adrenalitis and encephalomyelitis at sites of thermal injury. J Immunol 1968;100(6):1310–18.

118 Aarli JJ SJ Mork Myrseth E Glioblastoma associated with multiple sclerosis: Coincidence of induction? Eur Neurol 1989; 29:312–16.

119 Tourtellotte WW AR Potvin Baumhefner RW Multiple sclerosis de novo CNS IgG synthesis: effect of CNS irradiation. Arch Neurol 1980; 37:620–4.

120 Cook SD C Devereux Troiano R Total lymphoid irradiation in multiple sclerosis: blood lymphocytes and clinical course. Ann Neurol 1987; 22:634–8.

121 Cook SD C Devereux Troiano R Effect of total lymphoid irradiation in chronic progressive multiple sclerosis. Lancet 1986; 1:1405–9.

122 Devereux CK R Vidaver Hafstein MP Total lymphoid irradiation for multiple sclerosis. Int J Radiat Oncol Biol Phys 1988; 14:197–203.

123 Cook SD R Troiano Zito G Deaths after total lymphoid irradiation for multiple sclerosis. Lancet 1989; 2:277–8.

124 Scherer JJ. La ‘Glioblastomatose en plaques.’ J Belge Neurol Psychiat 1938; 38:1–17.

125 Munch-Peterson CJ. Case of disseminated sclerosis and glioma of the brain in the same patient. Acta Psychiat Neurol Scand 1949; 24:599–605.

126 Zimmerman HM Netsky MG. The pathology of multiple sclerosis. Res Publ Assoc Nerv Ment Dis 1950; 28:271–312.

127 Matthews WB. Epilepsy and disseminated sclerosis. Quart J Med 1962; 31:141–55.

128 Brihaye J O Perier Stenuit J. Multiple sclerosis associated with a cerebral glioma. J Neuropath Exp Neurol 1963; 22:128–37.

129 Boyazis RM L Martin Bouteille M Images histochimiques et ultrastructurales dans un cas de sclerose en plaques associee a un spongioblastome. Riv Pat Nerv Ment 1968; 88:1–20.

130 Barnard RO Jellinek EH. Multiple sclerosis with amyotrophy complicated by oligodendroglioma. J Neurol Sci 1967; 5:441–55.

131 Aubert L H Arroyo Dumas B Un can d’association entre sclerose en plaques et glioblastome cerebral. Rev Neurol 1968; 119:374–6.

132 Russell DS Rubenstein LJ. In: Pathology of tumours of the nervous system. 4th edition. London: Edward Arnold (Publishers) Ltd; 1977.

133 Mathews T Moosy J. Mixed glioma, Multiple sclerosis & Charcot-Marie-Tooth Disease. Arch Neurol 1972; 27:263–8.

134 Reagan TJ Frieman IS. Multiple cerebral gliomas in multiple sclerosis. J Neurol Neurosurg Psychiat 1973; 36:523–8.

135 Lynch PG. Multiple sclerosis and malignant gliomas (letter). BMJ 1974; 3:577.

136 Currie S Urich H. Concurrence of multiple sclerosis and glioma. J Neurol Neurosurg Psychiat 1974; 37:598–605.

137 Kalimo H H Frey Raine CS Late-onset malignant astrocytoma in a case of multiple sclerosis. Acta Neuropathol (Berl.) 1979; 46:231–4.

138 Lahl R. Combination of multiple sclerosis and cerebral glioblastoma. Eur Neurol 1980; 19:192–7.

139 Ho KL Wolfe DE. Concurrence of multiple sclerosis and primary intracranial neoplasms. Cancer 1981; 47:2913–19.

140 Vieregge P HC Nahser Gerhard L Multiple sclerosis and cerebral tumour. Clin Neuropathol 1984; 3(1):10–21.

141 Malmgren RM R Detels Verity MA. Co-occurrence of multiple sclerosis and glioma – case report and neuropathologic and epidemiologic review. Clin Neuropathol 1984; 3(1):1–9.

142 Nahser HC P Vieregge Nau HE Coincidence of multiple sclerosis and glioma. Surg Neurol 1986; 26:45–51.

143 Barnard RO Geddes JF. The incidence of multifocal cerebral gliomas. Cancer 1987; 60:1519–31.

144 Shankar SK TV Rao Srivastav VK Balo’s concentric sclerosis: A variant of multiple sclerosis associated with oligodendroglioma. Neurosurgery 1989; 25(6):982–6.

145 Perilongo G P Moras Carollo C Spontaneous partial regression of low-grade glioma in children with neurofibromatosis-1: A real possibility. J Child Neurol 1999; 14:352–6.

146 Costa MF SAP Novis Filho PN Esclerose Multipla, Ependimoma Medular E Meningioma Intracraniano. Arq Neuropsiquiatr 2000; 58(4):1133–7.

147 Adams RD Sidman RL. In: Introduction to Neuropathology. New York: McGraw-Hill; 1968; 34.

148 Okun MR Edelstein LM. Cell reproduction by subdivision? (letter) Lancet 1967; 1:1056–7.

149 Ferner RE RAC Hughes Johnson MR. Neurofibromatosis 1 and multiple sclerosis. J Neurol Neurosurg Psychiat 1995; 58:582–5.

150 Masson C Colombani JM. Neurofibromatosis 1 and multiple sclerosis. Apropos of a case. Rev Neurologique 1997; 153(11):684–6.

151 Alfonso S J Roquer Pou A. Multiple sclerosis and neurofibromatosis 1. Neurologia 1996; 11(6):233–5.

152 Pollock M C Calder Allpress S. Peripheral nerve abnormality in multiple sclerosis. Ann Neurol 1977; 2:41–8.

153 Hasson J RD Terry Zimmerman M. Peripheral neuropathy in multiple sclerosis. Neurology 1958; 8(7):503–10.

154 Almsaddi M TE Bertorini Seltzer WK. Demyelinating neuropathy in a patient with multiple sclerosis and genotypical HMSN-1. Neuromusc Dis 1998; 8:87–9.

155 Griffin JW Sheikh K. Schwann cell-axon interactions in Charcot-Marie-Tooth Disease. Ann NY Acad Sci 1999; 883:77–90.

156 Eisen A D Paty Hoirch M. Altered supernormality in multiple sclerosis peripheral nerve. Muscle Nerve 1982; 5:411–14.

157 Argyrakis A. Ultrastructural changes in peripheral nerves in multiple sclerosis and subacute sclerosing panencephalitis. In: Eds. Bauer HJ, Poser S, Ritter G. Progress in Multiple Sclerosis Research. Berlin: Springer-Verlag; 1980; 360–4.

158 Schoene WC S Carpenter Behan PO ‘Onion bulb’ formations in the central and peripheral nervous system in association with multiple sclerosis and hypertrophic polyneuropathy. Brain 1977; 100:755–73.

159 Rosenberg NL Bourdette D. Hypertrophic neuropathy and multiple sclerosis. Neurology 1983; 33:1361–4.

160 Ro YI CB Alexander Oh SJ. Multiple sclerosis and hypertrophic demyelinating peripheral neuropathy. Muscle Nerve 1983; 6:312–16.

161 Eisen A R Yufe Trop D Reduced neuromuscular transmission safety factor in multiple sclerosis. Neurology (Minneap) 1978; 28:498–602.

162 Weir A S Hansen Ballantyne JP. Single fiber electromyographic jitter in multiple sclerosis. J Neurol Neurosurg Psychiat 1979; 42:1146–50.

163 Hopf HC Eysholdt M. Impaired refractory periods of peripheral sensory nerves in multiple sclerosis. Ann Neurol 1978; 4:499–501.

164 Hopf HC. Electromyographic study on so-called mononeuritis. Arch Neurol 1963; 9:307–12.

165 Feigen I. Mesenchymal tissues of the nervous system, the indigenous origin of brain macrophages in hypoxic states and in multiple sclerosis. J Neuropathol Exp Neurol 1969; 28:6–23.

166 Feigen I Ogata J. Schwann cells and peripheral myelin within human central nervous tissues: the mesenchymal character of Schwann Cells. J Neuropathol Exp Neurol 1971; 30:603–12.

167 Cannella B D Pitt Marchionni M Neuregulin and erb B receptor expression in normal and diseased human white matter. J Neuroimmunol 1999; 100(1–2):233–42.

168 Huson SM PS Harper Compston DAS. Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain 1988; 111:1355–81.

169 Ferner RE R Chaudhuri Bingham J MRI in neurofibromatosis 1. The nature and evolution of increased intensity T2 weighted lesions and their relationship to intellectual impairment. J Neurol Neurosurg Psychiat 1993; 56:492–5.

170 Ratner N Genetic Daston MM. mechanisms cellular of Schwann cell tumour formation: neurofibromatosis type 1 and neurofibromatosis type 2. In: Eds. Jessen KR, Richardson WD. Glial cell development. 2nd edn. Oxford: Oxford University Press; 2001; 355–8.

171 Waxman SG. Multiple sclerosis as a neuronal disease. Arch Neurol 2000; 57:2–24.

172 Matthew PM N De Stefano Narayanan S Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Seminars in Neurology 1998; 18:327–36.

173 Lucchinetti CF W Brueck Rodriguez M Multiple sclerosis: lessons from neuropathology. Seminars in Neurology 1998; 18:337–45.

174 Narayana PA TJ Doyle Lai D Serial proton magnetic resonance spectroscopy imaging, contrast enhanced magnetic resonance imaging and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 1998; 43:56–71.

175 Gonen O I Catalaa Babb JS Total brain Nacetylaspartate: a new measure of disease load in multiple sclerosis. Neurology 2000; 54:15–19.

176 Fu L PM Matthews De Stefano N Imaging axonal damage in the normal appearing white matter in multiple sclerosis. Brain 1998; 121:103–13.

177 Evangelou N MM Esiri Smith S Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol 2000; 47:391–5.

178 Davie CA GJ Barker Webb S Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 1995; 118:1583–92.

179 Arnold DL GT Reiss Matthews PM Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol 1994; 36:76–82.

180 Bjartmar C RP Kinkel Kidd G Axonal loss in normalappearing white matter in a patient with acute MS. Neurology 2001; 57:1248–52.

181 Van Waesberghe JHTM W Kamphorst De Groot CJA Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 1999; 46:747–54.

182 Van Waderveen MAA L Truyen Van Oosten BW Development of hypointense lesions in T1-weighted spinecho magnetic resonance images in multiple sclerosis: relation to inflammatory activity. Arch Neurol 1999; 56:345–51.

183 Beaulieu C Allen PS. Determinants of anisotropic water diffusion in nerves. Magn Reson Med 1994; 31:394–400.

184 Pierpaoli C P Jezzard Basser PJ Diffusion tensor MR imaging of the human brain. Radiology 1996; 201:637–48.

185 Hajnal JV M Doran Hall A s Clinical use of diffusiontensor imaging for diseases causing neuronal and axonal damage. AJNR Am J Neuroradiol 1999; 20:1044–8.

186 Werring DJ CA Clar Barker GJ Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis. Neurology 1999; 52:1626–32.

187 Tivesky AL T Ptak Farkas J. Investigation of apparent diffusion coefficient and diffusion tensor anisotropy in acute and chronic multiple sclerosis lesions. AJNR Am J Neuroradiol 1999; 20:1491–9.

188 Sorensen AG O Wu Copen WA Human acute cerebral ischaemia: detection of changes by water diffusion anisotropy by using MR imaging. Radiology 1999; 212:785–92.

189 Guo AC JR Petrella Kurtzberg J Evaluation of white matter anisotropy in Krabbe disease using diffusion tensor MR imaging: initial experience. Radiology 2001; 218:809–15.

190 Fillipi M MA Rocca Minicucci L Magnetization transfer imaging of patients with definite MS and negative conventional MRI. Neurology 1999; 52:845–8.

191 Iannucci G C Tortorella Rovaris M Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. AJNR Am J Neuroradiol 2000; 21:1034–8.

192 Guo AC JR MacFall Provenzale JM. Multiple sclerosis: diffusion tensor MR imaging for evaluation of normal appearing white matter. Radiology 2002; 222:729–36.

193 Inglese M F Salvi Iannucci G Magnetization transfer and diffusion tensor MR imaging of acute disseminated encephalomyelitis. AJNR Am J Neuroradiol 2002; 23:267–72

194 Tortorella C B Viti Bozzali M A manetization transfer histogram study of normal appearing brain tissue in MS. Neurology 2000; 54:186–93.

195 Rovaris M B Viti Ciboddo G Brain involvement in systemic immune mediated diseases: magnetic resonance and magnetisation transfer imaging study. J Neurol Neurosurg Psychiatry 2000; 68:170–7.

196 Van Waesberghe JHTM MAA Van Walderveen Catelijns JA Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol 1998; 19:675–83.

197 Huppi PS B Murphy Maier SE Microstructural brain development after perinatal cerebral white matter injury assessed by diffusion tensor magnetic resonance imaging. Pediatrics 2001; 107:455–60.

198 Majoie CB EM Akkerman Blank C Mitochondrial encephalomyopathy: comparison of conventional MR imaging with diffusion-weighted and diffusion tensor imaging: case report. AJNR Am J Neuroradiol 2002; 23:813–16.

199 Fillipi M M Cercignani Inglese M Diffusion tensor magnetic resonance imaging in multiple sclerosis. Neurology 2001; 56:304–11.

200 Confraveux C. Relapses, progression, inflammation and neurodegeneration in multiple sclerosis: a changing view. Advances in Clinical Nerosciences and Rehabilitation 2002; 2(1):7–9.

201 Betemps EJ Buncher CR. Birthplace as a risk factor in motor neurone disease and Parkinson’s disease. Int J Epidemiol 1993; 22(5):898–904.

202 Poser CM. Trauma to the central nervous system may result in formation or enlargement of multiple sclerosis plaques. Arch Neurol 2000; 57:1074–6.

203 Cardoso F Jankovic J. Peripherally induced tremor and parkinsonism. Arch Neurol 1995; 52:263–70.

204 Jankovic J. Post-traumatic movement disorders: central and peripheral mechanisms. Neurology 1994; 44:2006–14.

205 Sibley WA CR Bamford Clark K A prospective study of physical trauma and multiple sclerosis. J Neurology Neurosurgery Psychiatry 1991; 54:584–9.

206 Kurtzke JF Beebe GW. Epidemiology of amyotrophic lateral sclerosis: 1. A case-control comparison based on ALS deaths. Neurology 1980; 30:453–62.

207 Kelly PJ Shapiro BE. Amyotrophic lateral sclerosis and other motor neurone disorders. In: Eds. Bachelor T, Gudkowicz MR. Principles of Neuroepidemiology. Boston: Butterworth; 2001; 265–87.

208 Morris HW NF Moriabadi Lees AJ Parkinsonism following electrical injury to the hand. Movement Disorders 1998; 13(3):600–02.

209 Chataway J A Mander Robertson N Multiple sclerosis in sibling pairs: an analysis of 250 families. J Neurology Neurosurgery Psychiatry 2001; 71:757–810.

210 Wolfgram F. What if multiple sclerosis isn’t an immunological or a viral disease? The case for a circulating toxin. Neurochem Res 1979; 4:1–14.

211 Van Noort J AC Van Sechel Bajramovic JJ The small heat-shock protein and ß crystalline as candidate autoantigen in multiple sclerosis. Nature 1995; 375:798–810.

212 McGrath J. Does ‘imprinting’ with low prenatal vitamin D contribute to the risk of various adult disorders? Med Hypotheses 2001; 56(3):367–71.

213 Palo J J Duchesne Wikstrom J. Malignant disease among patients with multiple sclerosis. J Neurol 1977; 216:217–22.

214 Spaar FW Wikstrom J. Multiple sclerosis and malignant neoplasm of the central nervous system. A clinical anatomical report of three cases. J Neurol 1978; 218:23–33.

215 Scully RE JJ Galdabani McNeely BU. Weekly clinicopathological exercise-Case 44. N Engl J Med 1978; 299:1060–7.

216De Caso R. Esclerose multipla, ependimoma medular e meningioma intracraniano. Arq Neuropsiquiatr 2000; 58:1133–7.